Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica

The goal of this observational registry is to characterize the clinical features, severity, treatments, and outcomes of patients with atopic dermatitis in Costa Rica receiving systemic and advanced therapies in routine clinical practice. The main questions it aims to answer are: What are the demographic and clinical characteristics of patients with moderate-to-severe atopic dermatitis treated in specialized dermatology centers in Costa Rica? What treatments are used in real-world practice and how do they impact disease severity and patient-reported outcomes over time? Participants with atopic dermatitis receiving systemic or advanced therapies as part of their usual medical care will be followed longitudinally, with collection of clinical severity scores, treatment patterns, and outcomes during routine visits.

NCT Number	NCT07448363
Lead Sponsor	Caja Costarricense de Seguro Social
Conditions	Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Dermatitis (Eczema), Atopic Dermatitis Patients, Atopic Dermatitis / Eczema, Atopic Dermatitis, Unspecified
Enrollment	50 participants
Start Date	2026-05
Primary Completion	2031-05 (estimated)
Study Completion	2031-05 (estimated)
Updated on ClinicalTrials.gov	2026-04-08